Esthésioneuroblastome : étude rétrospective et revue de la littérature

Lapierre, A.; Selmaji, Imade; Samlali, H.; Brahmi, T.; Yossi, S.

doi:10.1016/j.canrad.2016.05.015

Cited by 10 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our retrospective analysis does not include some casuistically rare types of HNC, which can be registered in the H&N region, due to their extreme rarity and lack of patients with such diagnoses in the period of data sampling. These rare tumor types are very rarely included in any statistical analysis and are most often just reported as individual cases [ 2 - 4 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Demographics of Head and Neck Cancer Patients: A Single Institution Experience

Stoyanov¹,

Kitanova²,

Dzhenkov³

et al. 2017

Cureus

View full text Add to dashboard Cite

IntroductionHead and neck cancer (HNC) comprises a diverse group of oncological entities, originating from various tissue types and organ localizations, situated in the topographical regions of the head and neck (H&N). This single institution retrospective study was aimed at establishing the HNC patient demographics and categorizing the individual incidence of H&N malignancies, regarding their organ of origin and main histopathological type.Materials and methodsAll histologically verified cases of HNC from a single tertiary referral center were reviewed in a descriptive retrospective manner. Data sampling period was 47 months.ResultsMale to female ratio of the registered HNC cases was 3.24:1. The mean age of diagnosis was 63.84 ± 12.65 years, median 65 years. The most common HNC locations include the larynx 30.37% (n = 188), lips and oral cavity 29.08% (n = 180), pharynx 20.03% (n = 124) and salivary glands 10.94% (n = 68), with other locations such as the external nose, nasal cavity and sinuses and auricle and external ear canal harboring a minority of the cases. The main histopathological groups include squamous cell carcinoma 76.74% (n = 475) and adenocarcinoma 6.14% (n = 38), with other malignant entries such as other epithelial malignancies, primary tonsillar, mucosa-associated lymphoid tissue or parenchymal lymphomas, connective tissue neoplasias, neuroendocrine and vascular malignancies diagnosed in a minority of cases.ConclusionConsidered to be relatively rare, HNC represents a diverse group of oncological entities with individual and specific demographic characteristics. The reported single institution results appear representative of the national incidence and characteristics of HNC.

show abstract

Section: Discussionmentioning

confidence: 99%

Demographics of Head and Neck Cancer Patients: A Single Institution Experience

Stoyanov¹,

Kitanova²,

Dzhenkov³

et al. 2017

Cureus

View full text Add to dashboard Cite

show abstract

“… 30 , 31 In 2011, Noh et al 32 concluded that ENI for ON plays a limited role in preventing cervical nodal failure and that omitting ENI may be an option in patients affected by advanced disease treated with a combination of RT and chemotherapy. In the study of Lapierre et al 27 none of the patients received prophylactic cervical irradiation and there were two recurrences (28%) in the neck nodes. Relapses were treated by surgery in one patient and by the combination of surgery and adjuvant RT in the other patient.…”

Section: Discussionmentioning

confidence: 93%

“…With regard to the RT technique, when the tumour involves adjacent structures such as the infraorbital canal or optic nerve, IMRT is recommended because it better preserves closer structures. 23 , 26, 27 In our clinical case, a combined strategy consisting of endoscopic surgery and adjuvant IMRT was chosen.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, Mori et al used 50 to 66 Gy as postoperative RT, 40 Gy as preoperative RT and 54 to 66 Gy in the setting of sequential chemoradiation therapy. In the absence of randomized studies, Lapierre et al 27 recommended the doses currently used in the treatment of other sinonasal tumours, between 60 and 70 Gy in 30–35 fractions based on tumour site, pathological characteristics and quality of surgical resection. In our clinical case, we delivered a total dose of 60 Gy in 30 fractions (2 Gy daily) because this is the schedule we used in the postoperative setting for sinonasal tumours and because the patient underwent a wide tumour excision by nasal endoscopic surgery with negative margins.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature

et al. 2018

View full text Add to dashboard Cite

Olfactory neuroblastoma (ON) is a rare tumour of the olfactory neuroepithelium that is characterized by a pattern of slow growth and local recurrences. Combination of surgery and radiotherapy, with or without chemotherapy, is considered to be the standard of care for primary site disease. Recent literature supports the view that endoscopic resection followed by adjuvant radiotherapy correlates with better outcome. In this short communication, we present a case report of olfactory neuroblastoma arising in the right nasal sinus in a 34-year-old male. This patient was treated with endoscopic resection and external beam radiotherapy to the right nasal sinus with intensity-modulated radiation therapy (IMRT) technique. After 2 years follow-up, the patient is free of tumour without any late effect related to therapies. We believe that, in such patients, a treatment strategy including endoscopic resection followed by adjuvant radiotherapy may be effective and feasible and should be considered the gold standard of care.

show abstract

“…It is worth noting that in two studies delayed administration of radiation post-surgical resection was associated with a higher probability of disease recurrence and metastasis suggesting the necessity of fast and aggressive introduction of adjuvant radiation therapy early after surgical resection [15,19,21]. When comparing two groups, the first receiving radiation therapy post-surgery and the other group receiving it six weeks to two months’ post-surgery, the authors found that although the patients receiving the radiation therapy immediately post-surgery had slightly higher levels of toxicity than the patients who did not receive it promptly, they did better than the delayed group in the disease-free time and time to recurrence with metastasis [20].…”

Section: Reviewmentioning

confidence: 99%

Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival

Alotaibi

Priola

Bernat

et al. 2019

Cureus

View full text Add to dashboard Cite

Esthesioneuroblastoma (ENB) is a rare malignant tumor of the nasal cavity. The genetic basis of its development is still under study and has not been fully delineated. It has varying symptoms depending on the lesion’s location within the nasal cavity. The most commonly used systems for such lesions are the Kadish staging and Haymes grading systems. The objectives are to review the most recent published literature evaluating the different treatments/ combination of treatment and assess the most appropriate treatment modality that can provide the longest progression-free survival and overall survival for ENB patients. Moreover, a look at what the latest literature suggests when it comes to adjuvant treatments and their effect on survival is also key to further the body of knowledge for neurosurgeons, Ears, Nose, and Throat (ENT) physicians and all the different subspecialties that deal and serve these population of patients. The published literature was reviewed starting from 1990. The focus was made on single-center experiences given their availability and easy access. The most recently published systematic review was used as the benchmark; research published after that was included in this study. The database search in OVID was conducted using the following keywords: “Esthesioneuroblastoma”, “ENB”, “Olfactory Neuroblastoma”, Nose neoplasm”, skull base neoplasm”, “radiation”, and “resection”. The database search found 17 papers which included 14 single-center reports, one systematic review, and two nationwide multi-center reviews. Surgery plus adjuvant radiation therapy appears to provide the best overall survival and progression-free survival especially in patients with high Kadesh grade. On the other hand, surgery alone or biopsy followed with radiation therapy provided the lower progression-free survival and overall survival from time of diagnosis. The role of chemotherapy, however, requires further investigation to assess its potentially harmful effects. The use of surgery as a stand-alone modality of treatment should be cautiously and rarely used in patients with lower staging scores and multiple negative resection margins.

show abstract

Esthésioneuroblastome : étude rétrospective et revue de la littérature

Cited by 10 publications

References 47 publications

Demographics of Head and Neck Cancer Patients: A Single Institution Experience

Demographics of Head and Neck Cancer Patients: A Single Institution Experience

Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature

Esthesioneuroblastoma: Summary of Single-center Experiences with Focus on Adjuvant Therapy and Overall Survival

Contact Info

Product

Resources

About